Phthalate and BPA exposure in women and ... - ACS Publications

14. 3. Foods Directorate, Health Canada. Ottawa. ON. Canada. 15. 4. Centre de Toxicologie du Québec (CTQ), Institut National de Santé Publique du Qu...
0 downloads 0 Views 671KB Size
Subscriber access provided by Université de Strasbourg - Service Commun de la Documentation

Environmental Measurements Methods

Phthalate and BPA exposure in women and newborns through personal care product use and food packaging. Mandy Fisher, Tye Arbuckle, Susan MacPherson, Joseph M. Braun, Mark Feeley, and Éric Gaudreau Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.9b02372 • Publication Date (Web): 19 Aug 2019 Downloaded from pubs.acs.org on August 21, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 38

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Environmental Science & Technology

Phthalate and BPA exposure in women and newborns through personal care product use and food packaging. Mandy Fisher1*, Tye E. Arbuckle1, Susan MacPherson1, Joseph M. Braun2, Mark Feeley3, Éric Gaudreau4

1. Population Studies Division, Environmental Health Science and Research Bureau, Health Canada. Ottawa, ON. Canada 2. Department of Epidemiology, Brown University, Providence, RI. U.S.A. 3. Foods Directorate, Health Canada. Ottawa. ON. Canada 4. Centre de Toxicologie du Québec (CTQ), Institut National de Santé Publique du Québec (INSPQ), QC. Canda

18 19

*corresponding author

20 21 22 23 24 25 26

Health Canada, Population Studies Division 269 Laurier Avenue W Ottawa, Ontario K1A 0K9 Canada Mail Stop 4908, Room 8-128 Phone: 613-946-7496 Email: [email protected]

27 28

Targeted Journal: Environmental Science and Technology

1 ACS Paragon Plus Environment

Environmental Science & Technology

29 30

Page 2 of 38

Abstract

31 32

Phthalates and bisphenol A (BPA) are used in some personal care products (PCPs) and

33

containers for food processing and packaging. The Plastics and Personal-Care Product use in

34

Pregnancy (P4) Study (2009-10) explored the association between PCP use during pregnancy

35

and the postpartum period among 80 pregnant women and 55 infants and BPA and phthalate

36

concentrations in multiple maternal and infant urine specimens collected throughout the study

37

(n=1260 samples). The type, frequency and timing of PCP and food packaging use 24 h before

38

and during the urine collection period was collected at 5 time points for the mother using

39

prospective diaries. Infant urine was collected up to 2 times before 3 months of age and mothers

40

answered questions about infant feeding and PCP use on their baby. In mothers, monoethyl

41

phthalate (MEP) metabolite concentrations were significantly higher when women reported

42

using makeup or body lotion in the last 24h. MEP concentrations were consistently higher when

43

the usage occurred within 0-6 h before the urine sample collection for almost all of the PCP

44

categories. Infant lotion or baby powder application in the previous 24h was associated with

45

higher phthalate metabolite concentrations in infants.

46

were lower in exclusively breastfed infants compared to those who were exclusively formula-fed

47

or breastfed with supplementation. Given that PCPs tend to undergo frequent formulation

48

changes, which could impact the relative importance of a certain product type as a source of

49

exposure, continued research of this type is warranted.

Total BPA metabolite concentrations

50 51 52

2 ACS Paragon Plus Environment

Page 3 of 38

53 54 55

Environmental Science & Technology

Introduction Both phthalates and bisphenol A (BPA) are chemicals used in some cosmetics, personal 1,2.

56

care products (PCPs), food packaging materials and medications

57

have been measured in urine, blood, cord blood, human milk, amniotic fluid, follicular fluid,

58

meconium, saliva, sweat, dust and air 3-17.

59

They are ubiquitous and

Phthalates and BPA are both suspected endocrine disrupting chemicals

18-20.

Phthalates

60

have shown associations with abnormal sperm quality, preterm birth, growth restriction, and

61

gestational hypertension

62

development (anogenital distance), allergies, asthma and behaviour 24-27.

63

utero, infancy) to BPA and phthalates may increase the risk of neurodevelopmental disorders in

64

children by disrupting hormone-mediated processes during critical windows of development 28,29.

65

1,21-23.

In children, associations have been seen with sexual

Studies of pregnant women

30-37

Early life exposure (in

show increased concentrations of urinary phthalates 30-32,34,36,

66

mainly among users of leave-on PCPs including: makeup or cosmetics

hair spray or

67

hair products 31,36, lotion 30,36,37 or sunscreen 31,33, deodorant 30,36,37, nail polish 30,36 and perfume

68

30-32,35-37.

69

in the last 24 h has shown associations with phthalates

70

between PCP use and BPA, however, consuming foods in metal cans has been associated with

71

increased urinary levels of BPA39.

72

Much of the previous research on pregnant women has evaluated exposure by measuring

73

between 1 to 3 spot urine samples and examining the association with recalled PCP use over the

74

past 24 30,36 to 48 31,32,35,37 hours, past 7 days 33 or estimated frequency of use in a week or month

75

at specified time periods

76

studies in women show moderate to high reproducibility of these chemicals across a day 43,44, but

77

higher variability across the entire pregnancy

78

multiple spot urine samples in a 24 h period, for non-pregnant women, and showed both positive

79

and negative associations of urinary phthalates with both leave-on and wash-off PCPs.

In infants, mothers’ reported use of infant lotion and powder as well as baby shampoo

33,34.

38.

Few studies have shown association

These chemicals have very short half-lives (6 to 24 h) with phthalate or total BPA concentrations,

379

suggesting that food packaging may not be an important source of phthalate and BPA exposure

380

in this population, or that we did not have enough statistical power to detect such associations. It

381

has been suggested that the elimination half-life of dietary exposure to some phthalates can be as

382

short as 3 h 42 and less than 6 h for BPA40-42.

383

Medication Form

384

We examined the association between medication form (tablet, or capsule) and the

385

percent changes in total BPA urine concentrations and phthalate molar sums but we did not

386

observe consistent results (See Supplementary Table S5). Consuming medication in capsule form

387

in the past 24 h was associated with a 27% (95% CI: -4%, 69%), 75% (95% CI: -2%, 212%),

388

68% (95% CI:-18%, 247%) and 22% (95% CI: -3%, 55%) percent increase in concentrations of

389

MEP, ∑DiBP, ∑DiNP and total BPA respectively.

Various phthalates, including DEP, DBP, 13

ACS Paragon Plus Environment

Environmental Science & Technology

Page 14 of 38

390

DMP, and dioctylphthalate are used as non-medicinal ingredients in numerous types of enteric-

391

coated and delayed-release capsules, as well as controlled-released transdermal films

392

contrast, consuming tablet form medication in the past 24 h was associated with a significant

393

decrease in urinary ΣBBzP (-45%; 95% CI:-61%,-22%) and MEP (-31%; 95% CI: -49%, -5%)

394

concentrations. We have no explanation for this finding, unless the medication type might have

395

increased excretion of contaminants from the body, or it is a chance finding. Due to our very

396

limited sample size, we were not able to investigate further into the medication types. We did

397

not find any significant associations between medication form and phthalates or total BPA

398

concentrations in maternal urine, but consuming medication in capsule form in the previous 24 h

399

was associated with non-significant increases in MEP (27%, p=0.09) and ΣDiBP (86%, p=0.07)

400

concentrations.

67.

In

401

Exposure to medication with phthalates as non-medicinal ingredients has been previously

402

reported. In a case study, Hauser et al. 68 described a man who took a medication for ulcerative

403

colitis (Asacol) with DBP urinary concentrations (16,868 µg/L) that were more than 2 orders of

404

magnitude higher than the 95th percentile in NHANES (1999-2000). DBP is still used in the

405

enteric coating of some, but not all medications containing mesalamine, the active ingredient in

406

commonly prescribed medications for inflammatory bowel diseases

407

over/cross-back study of men taking mesalamine, with and without DBP used in the enteric

408

coating, it was found that the combination of mesalamine and DBP disrupted serum levels of

409

pituitary and gonadal hormones. This effect was reversed after removal of the DBP exposure

410

among men who did not have long-term exposure to medication with high concentrations of

411

DBP69. Alterations were also seen for thyroid hormones 70 and semen parameters 71 in this same

412

study. Messerlian et al.72 showed an increase in DEHP metabolites following dermal application

413

of ultrasound gel during routine obstetrical scans at 20 weeks. Using results from NHANES

414

(from 1999-2000 through 2013-2014) Romano et al.73 found an association between regular use

415

of multivitamin/multimineral supplements and increased concentrations of MEP (11% higher),

416

compared to non-users; however, no association was seen with MBP. Given that medications

417

and supplements can be an important source of long-term exposure, the proportional contribution

418

to a person’s total phthalate exposure, relative to other sources, should be further explored.

419

67.

In a recent cross-

Infants & PCPs

14 ACS Paragon Plus Environment

Page 15 of 38

Environmental Science & Technology

420

Infants who used lotion in the past 24 h (applied by caregiver) had significantly higher

421

geometric mean phthalate metabolite concentrations of MBzP, MCPP, and MBP (See Figure 4).

422

The percent change in molar sum concentrations for infants who had lotion applied in the past 24

423

h was 163% (95% CI: 11%, 522%), 200% (95% CI: 41%, 539%), and 96% (95% CI: 17%,

424

227%) for these phthalates, respectively, compared to infants without application. Although

425

only 4 infants had baby powder applied to them in the last 24 h, we showed high, however

426

imprecise, associations with MBzP (324%; 95% CI: -2%, 1740%); , MBP (200%; 95% CI: 27%,

427

610%) and total BPA (466%; 95% CI: -40%, 5216% ) concentrations, compared to those infants

428

who did not have baby powder applied.

429

explored this further and found that the percent change was still near 200% when we removed

430

one infant whose total BPA concentrations were near the 95th percentile. However, if we

431

assume that the mothers of these babies applied the baby powder, we did not see high total BPA

432

concentrations in the mothers urine (median 1.18 µg/L (range 0.87-2.4) compared to 1.21 µg/L

433

in the full study).

Given the low number of users of baby powder, we

434

When we compared the geometric mean infant urine concentrations of low (≤2), medium

435

(3) and high (≥4) product users, we observed increased geometric mean concentrations for total

436

BPA (145%; 95% CI:-43%, 948%), MCPP (62%, 95% CI:-28%, 264), MBP (71%; 95% CI:2%,

437

187%), and MBzP (78%, 95% CI:-26, 332) among high product users compared to low product

438

users; however they were not statistically significant (See Supplementary Figure S2).

439

change in total BPA and phthalate urinary concentrations were association with the amount of

440

time per day that the child spends using soft plastic toys, teething rings, or a pacifier (See SI

441

Table S6 and S7). The use of a pacifier during sleep within the past 24 h was associated with a

442

non-significant increase (154%; 95% CI:-63%, 1626) in urinary total BPA concentrations.

No

443

Very few studies have examined the relationship between infant exposures to phthalates

444

and total BPA and product use. In the Study for Future Families, in the U.S. (1999-2002), infant

445

(n=154) urinary phthalate concentrations were associated with mothers’ reported use of infant

446

lotion (MEP, MMP), infant powder (MiBP) and baby shampoo (MMP) in the last 24 h 38. This

447

association was strongest for infants who were